InflaRx Raises Financing to Develop a New Therapeutic Approach against Sepsis

InflaRx GmbH, announced today the closing of its seed financing
led by Affentranger Associates alongside with bm-t
beteiligungsmanagement thuringen gmbh. InflaRx´s mission is to develop
new therapeutic approaches to prevent and treat sepsis. Created by
Prof. Niels Riedemann and Prof Renfeng Guo, two worldwide recognized
researchers in the field of inflammation and sepsis, InflaRx has
already brought its leading development program targeting activation
products of the complement system in an advanced pre-clinical stage.

"Aware of many targets which have failed in the past, we are
developing a new breakthrough approach to address the sepsis
indication by combining our state of the art R&D program with the
worldwide recognized clinical sepsis research center in Jena" says
Prof. Niels Riedemann CEO of InflaRx. "The high potential of InflaRx
of addressing a critical unmet medical need with a new very promising
target and a clear clinical strategy has been recognized by the seed
investor group" adds Nicolas Fulpius, Chairman of the board of InflaRx
and Partner at Affentranger Associates. "The competence of InflaRx
will create strong synergies for Jena as fast growing center of sepsis
expertise" underlines. Dr. Guido Bohnenkamp, Managing Director of
bm-t.

As of today, sepsis - also called blood poisoning in the public
press - is the most frequent cause of death in non-cardiological
intensive care units worldwide. With over 1.5 million cases in Europe
and North America alone, and with mortality rates up to 50%, sepsis
remains one of the largest and least publicly recognized unmet medical
needs.

Based in Jena (Germany), a worldwide recognized sepsis research
hub , InflaRx is developing its innovative therapeutic programs in
cooperation with the University Hospital of the Friedrich Schiller
University in Jena, the University of Michigan in USA and Beijing
Mabworks Biotech Co., LTD in China. The Scientific Advisory Board of
InflaRx is composed by two world leaders in the field of basic sepsis
research with Prof P. Ward at the University of Michigan and clinical
sepsis research with Prof. K. Reinhart at the
Friedrich-Schiller-University in Jena.

About Affentranger Associates SA

Incorporated in 2002, Affentranger Associates is a Switzerland
based business platform focused on the theme of value creation and
active management. As principal investor, the company has the ambition
to achieve sustainable long-term returns by investing with a
combination of management and capital in high-growth potential
companies. Affentranger Associates has offices in Geneva and Zurich.

About bm-t beteiligungsmanagement thuringen gmbh

The bm-t, a daughter company of the Thuringer Aufbaubank, acts as
the management company of four Thuringen dedicated investment funds,
the TI - Thuringer Innovationsfonds, VCT - Venture Capital Thuringen,
TIB - Thuringer Industriebeteiligungs and the PET - Private Equity
Thuringen. As of today, the bm-t manages a portfolio of more than 40
companies located in Thuringen (Germany) for a total of more than EURO
165M under management.